欢迎参加2024肝病新药联盟年会暨减重新药论坛!当地时间2024年11月22日,BridgeBio Pharma(BridgeBio)宣布FDA批准了研发的转甲状腺素蛋白心脏淀粉样变性心肌病(ATTR-CM)新药——Attruby(acoraamidis)上市。BridgeBio在其发布新闻稿中写道:“acoraamidis是第一个,也是唯一一个在标签中正式注明能几乎/完全稳定转甲状腺素蛋白(...
Source Link欢迎参加2024肝病新药联盟年会暨减重新药论坛!当地时间2024年11月22日,BridgeBio Pharma(BridgeBio)宣布FDA批准了研发的转甲状腺素蛋白心脏淀粉样变性心肌病(ATTR-CM)新药——Attruby(acoraamidis)上市。BridgeBio在其发布新闻稿中写道:“acoraamidis是第一个,也是唯一一个在标签中正式注明能几乎/完全稳定转甲状腺素蛋白(...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.